Tenecteplase For Ischemic Lacunar Stroke "TNKilas"

Recruiting

Phase N/A Results

Summary of Purpose

To examine the efficacy of intravenous tenecteplase to treat acute lacunar type of ischemic strokes within 24 hours of the initial symptom onset.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 March 2010.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Genentech, PDL BioPhama, Sanofi-Aventis, Boehringer Ingelheim, Pfizer.

Trial Design

Multi-center, treatment, pilot study.

Contacts

  • Judy Beck

    dwang@uic.edu